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Mechanism of chemoprevention by daidzein (500μg/g bwt) was examined by injecting it subcutaneously at 16th, 18th, and 20th
daypostpartum,followedbycountingofterminalendbuds(TEBs),terminalducts(TDs),andlobulesandimmunohistochemistry
of ER-α, Bcl2, Bax, and caspase-3. DNA fragmentation was also analysed to measure the apoptosis level. Estradiol benzoate (EB)
(500ng/g bwt) and dimethyl sulphoxide (DMSO) were used as reference and vehicle, respectively. Observations show a signiﬁcant
enhancementofmammaryglanddiﬀerentiationatpostnatalday21(PND21)aswellasPND50.There wasa signiﬁcantdecrease of
ER-α expressionatPND21 andincreaseinitsexpressionatPND50,indaidzein-treated animals.The ratioofexpressionofBcl-2to
Bax proteins increased at PND50 the same whereas, it decreased at PND50 due to daidzein. An increased expression of caspase-3
and DNA fragmentation was also seen due to daidzein at PND50. The mammary gland of EB-treated animals showed response a
somewhatsimilar to that of daidzein-treated animals.
1.Introduction
Phytoestrogens, naturally occurring hormone-like com-
pounds with a unique diphenolic structure found in several
plants [1], have received much attention as dietary compo-
nents as they are known to promote better health. Phytoe-
strogens have been also associated with reduced incidence
of various cancers, cardiovascular disease, and osteoporosis
and lower cholesterol level [2–5]. Some studies suggest that
the dietary intake of phytoestrogens decreases the risk of
breast cancer in humans [6, 7]. The most extensively studied
phytoestrogen in vitro and in vivo is genistein which is found
richly in soybeans. However, biological activities of many
other naturally occurring isoﬂavones have not been studied
in detailtill now. The phytoestrogen daidzein is an isoﬂavone
present as a glucoside in many plants used in human diets.
Daidzein is especially concentrated in soy and soy-based
products used for human consumption [8, 9]. A higher inci-
dence of breast cancer in Western population is seen as com-
pared to Asians who consume diet containing relatively high
levels of low-fat, high-ﬁbre, high-soya content [10]. Asian
women show protection against breast cancer in comparison
to women living in USA or Britain [11, 12]w h i c hi sb e l i e v e d
to be lost upon immigration and exposure to Western
lifestyles within a few generations [13]. These studies suggest
that exposure to phytoestrogens at an early stage is extremely
important, in order to gain their cancer-preventive eﬀects.
The female mammary gland undergoes cell division dur-
ing puberty, and throughout adult life there is cyclical pro-
liferation and involution during the estrous cycle. During
early development, rising endogenous estrogen promotes
mammary duct branching which ends in highly proliferative
structures, terminal end buds (TEBs) [14]. At postnatal day
(PND) 21, the number of TEBs is maximal, and at puberty
the onset of estrous cycles results in changing progesterone
and estrogen levels that promote diﬀerentiation of TEBs
to the less proliferative alveolar buds or lobules [15–17].
Highest number of tumours per animal was observed when
carcinogen exposure occurred in rats at postnatal day 40–
50, a time when mammary gland exhibits a high density of2 ISRN Oncology
the highly proliferative TEBs [15]. The incidence of car-
cinomas is positively correlated with the number of TEBs
in mammary gland of the young virgin rat at the time of
carcinogen exposure [16, 17]. Administration of the phytoe-
strogen genistein to neonatal and prepubertal rats reduced
TEBs by promoting TEB diﬀerentiation [18, 19].
A study on Sprague Dawley rats (mammary tumor mod-
el) shows that daidzein has been an eﬀective inhibitor of
DMBA-induced mammary tumor [20]. Chemoprevention
study from our lab has also shown a decrease in tumor bur-
den and incidence by prepubertal daidzein administration
[21]. Although daidzein also has the ability to bind to the
ERs [22], the precise mechanism of action by which it shows
a chemopreventionagainst breast cancer has not been clearly
elucidated. Considering the above literature, it could be
hypothesized that daidzein could also aﬀect the diﬀerenti-
ation and signaling pathways as a mechanism of chemo-
prevention. Hence, to explore the mechanism of actions of
daidzein, its eﬀect on cell proliferation, mammary gland
diﬀerentiation, and the expression of ERs in a prepubertal
mammary tumour model was carried out.
2.Materialsand Methods
2.1. Chemicals. Daidzein, estradiol benzoate (EB), and
Hoechst 33258 were bought from Sigma Aldrich Co. (St.
Louis, Mo, USA), while dimethyl sulphoxide (DMSO) and
carmine were bought from Qualigens (India). Primary anti-
bodies for ER-α, Bcl2. Bax, and caspase-3 were bought from
Santa Cruz Biotechnology, Inc., Santa Cruz, Calif, USA,
and secondary antibodies, diaminobenzidine (DAB), avidin-
biotin complex, and normal Goat Serum (NGS) were pur-
chased from Bangalore Genei (India).
2.2. Animals. Female Sprague Dawley rats, kept in animal
facility in a 12hr day:12hr night cycle, and maintained in
the animal house of the university were used for the present
study.Standardfeedandwaterwereprovidedad libitum.The
studies were conducted according to the ethical guidelines
of Committee for Control and Supervision of Experiments
on Animals, Government of India, on the use of animals for
scientiﬁc research.
2.3. Experimental Design. The whole investigation was car-
ried out under two major experiments.
Experiment 1. A total of thirty-six animals (female Sprague
Dawley oﬀsprings) of the same age were divided into 3
groups of 12 each. On postnatal days 16, 18, and 20, while
group II and III were injected subcutaneously with 500μg/g
body weight daidzein and 500ng/g body weight of estradiol
benzoate(EB),respectively[19,23],anequalvolumeofvehi-
cle (DMSO) was injected to the animals of group I (Control,
DMSO). On the 21st day, 18 hours after the last injection, 6
animals from each group were sacriﬁced and the rest of the
6 were maintained till the 50th day and sacriﬁced thereafter.
The mammary glands obtained at both times (PND21 and
PND50) were preserved for diﬀerentiation study.
Experiment 2. In another 36 animals, a similar experiment
was repeated. However, this time the mammary glands ob-
tained at PND21 and PND50 were stored for immuno-
histochemical experiments.
2.4. Mammary Gland Diﬀerentiation. All mounts of fourth
pair of the mammary gland of the animals were prepared.
Mammary glands were dissected at the time of sacriﬁce,
spread on the microscope slide, and then placed in neutral
buﬀeredformalin for8h(22-day-oldanimals) andovernight
(50-day-oldanimals). Glands weredefattedinacetonefor4h
or overnight, placed in 70% alcohol for 30 min, hydrated in
water (15min), and stained in alum carmine for overnight.
After staining, glands were run through a series of graded
alcohols (30–100%ethanol) and placed in xylene to clearthe
tissue. Glands were thencompressed betweentwo glassslides
for 24h, released and allowed to expand for at least 8h, and
ﬁnally mounted using a glass coverslip and DPX. All mounts
were then evaluated via light microscopy using the criteria
established by Russo and Russo [16, 17] and Murrill et al.
[19]. All mounts were evaluated for the number of terminal
end buds, terminal ducts, and lobules type I by the help of
the software ImagePro [19].
2.5. Immunohistochemistry (ER-α, Bcl2, Bax, Caspase-3).
The mammary glands dissected were ﬁxed in 10% neutral
buﬀered saline, and sectioning was done by cryostat at
20 microns. Sections were treated with 10% normal goat
serum (NGS) for 2h for blocking and then incubated in the
primary antibody for3daysat4◦C.Theantibody wasdiluted
in 0.1M PBS containing 5% NGS and 0.5% triton-X-100.
After being washed in PBS, the sections were incubated in
biotinylated goat antimouse IgG at 1:200 for 18h at 4◦C.
Following this secondary antibody step, the sections were
washed and placed in preformed avidin-biotin peroxidase
complex (ABC) at 1:400 dilutions for two hours at room
temperature. For visualizations of the reaction sites, the
sections were treated with the chromogen diaminobenzidine
(DAB)andhydrogenperoxidefor2-3min.The sectionswere
rinsed with distilled water dehydrate in ethanol and cover-
slipped with distyrene plasticizer xylene (DPX) mounting
medium.
2.6. Nuclear Staining. The nuclei were stained with Hoechst
33258 (Sigma); 10μm sections were mounted on gelatin-
coated slides and washed in PBS for 10min (Figure 6). They
were incubated with Hoechst 33258 (1μg/mL) for 30min
in dark at room temperature. After washing twice with PBS
(5min each) and once with distilled water (5min), the slides
were coverslipped with 10% glycerol and stored in dark. The
slides were viewed in a ﬂuorescent microscope under the
blue ﬁlter (excitation wavelength= 343nm, emission wave-
length= 483nm). Since Hoechst is membrane permeant, the
procedure does not require membrane permeablization.
2.7. Analysis. Immunostaining was evaluated by examina-
tion of slides under a bright ﬁeld microscope (Carl Zeiss
Axioscop Mot 2) at magniﬁcation 400x, and images wereISRN Oncology 3
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Figure 1: Eﬀect of daidzein (500μg/g bwt) on diﬀerentiation of mammary gland through count of TEBs, TDs, and lobules, in prepubertal
female Sprague Dawley rats at PND21 and PND50. (a) All mounts of mammary glands. Mean percent change ± SEM in the count of (b)
TEBs, (c) TDs, and (d) lobules, from 6 animals. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, compared to the respective value in control group.
capturedthrougha digitalcamera formeasurement ofinten-
sity and counting of cells. Intensities of immunostained cells
were estimated by densitometry using morphometric soft-
ware Scion Image. In order to count the number of ER, Bcl2,
Bax, Caspase-3 positive cells and Hoechst stained apoptot-
ic nuclei, magniﬁed views (400x) of sections were cap-
tured. The total cells (unstained) and immunostained cells
were counted with the help of the software ImageTool
(UTHSCSA). Values were compared using one-way ANOVA
(Sigma Stat, Jandel Scientiﬁc).
3.Results
3.1. Mammary Gland Diﬀerentiation. Diﬀerentiation of
mammary gland was studied by observing the branching of
mammary gland and the terminal end buds and ducts and
lobular count at two diﬀerent stages (i.e., PND21 and
PND50) after a prepubertal exposure of daidzein to the an-
imals. An increase in the count of TEBs, TDs, and lobules
has been seen in the daidzein-treated rat mammary glands
at PND21, whereas there is a decrease in the TEB and TD
count and further increase of lobule I count at PND50 as
compared to the control, as shown in Figure 1.As i m i l a r
signiﬁcant increase of TEBs, TDs, and lobules has also been
seen in the EB-treated animals at PND21, and a decrease is
seen in TEBs and TDs and an increase in mammary gland
lobules at PND50.
3.2. Immunostaining of ER-α. Immunohistochemistry re-
sults at PND21in daidzein-and EB-treated mammary glands
showed that the percentage ER+ cell count decreased signif-
icantly, that is, 41.92 ± 1.0%, P<0.001 and 39.21 ± 0.8%,4 ISRN Oncology
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Figure 2: Eﬀect of daidzein (500μg/g bwt) on ER-α. (a) Immunohistochemistry of ER-α in prepubertal female Sprague Dawley rats at
PND21 and PND50. (b) mean percent change ± SEM of ER-α+ cell count and (c) mean ± SEM of densitometric analysis, from 6 animals.
∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, compared to the respective value in control group.
P<0.05, as compared to the control (45.7 ± 0.5%), where-
as intensity of daidzein-and EB-treated epithelial cells de-
creased up to 80.9%, P<0.001, and 82.8%, P<0.001, resp-
ectively, as compared to the control (100%). At PND50,
daidzein-and EB-treated mammary gland epithelial cells in
both the count and intensity were shown to be increased
signiﬁcantly. The percentage count of ER+ cells increased to
39.2 ± 0.7%, P<0.001, and 41.54 ± 0.7%, P<0.001, in
daidzein-and EB-treated epithelial cells respectively, from
control (33.65 ± 0.57%), and intensity increased to 121.5%,
P<0.001, and 125.4%, P<0.01, in daidzein-and EB-
treated epithelial cells, respectively from control (100%) sig-
niﬁcantly.
3.3. Evaluation of Bcl2/Bax Ratio. In 21-days-old mammary
glands, the Bcl2+ cell count and intensity were found to be
increased signiﬁcantly in daidzein-treated animals (40.26 ±
0.38%, P<0.001; 111%, P<0.01) as well as in the EB-treat-
ed animals (44.16 ± 1.02%, P<0.001; 122.4%, P<0.001)
from control (35.9 ± 0.6%, 100%), whereas the cell count
and intensity of Bax+ cells were decreased signiﬁcantly in
daidzein-treated animals (19.37 ± 0.22%, P<0.05; 82.0%,
P<0.001) as well as in EB-treated animals (19.7 ± 0.68%,
P<0.05; 83.6%, P<0.05) from control (23.61 ± 0.91%,
100%). In 50-days-old mammary glands, Bcl2+ cell count
and intensity were decreased signiﬁcantly in daidzein-treated
animals (31.3 ± 0.64%, P<0.001; 82.3%, P<0.01) as well
as in the EB-treated animals (29.11 ± 0.65%, P<0.001;
79.5%, P<0.01) from control (40.4±0.65%, 100%). Simul-
taneously, the cell count and intensity of Bax+ cells were
increased signiﬁcantly in daidzein-treated animals (40.65 ±
0.67%,P<0.001;114%,P<0.05)andintheEB-treatedcells
(39.0 ± 0.84%, P<0.001; 116.3%, P<0.01) from control
(28.05 ± 0.37%, 100%). Bcl2/Bax ratio was found to be
e n h a n c e di nm a m m a r yg l a n da tP N D 2 1b u tn o ta tP N D 5 0 .
3.4. Evaluation of Apoptosis. Caspase-3+ cell count percent-
age was shown to be increased signiﬁcantly at 50 days inISRN Oncology 5
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Figure3:Eﬀect ofdaidzein(500μg/gbwt) onBcl2.(a)ImmunohistochemistryofER-α inprepubertal femaleSpragueDawley ratsatPND21
andPND50. (b) meanpercent change ± SEMofER-α+ cell countand(c)mean ±SEM ofdensitometric analysis,from6animals. ∗P<0.05,
∗∗P<0.01, ∗∗∗P<0.001, compared to the respective value in control group.
mammary glands treated with daidzein (20.57 ± 1.07%, P<
0.05) and EB (23.39 ± 1.21%, P<0.001) as compared to
the control mammary glands (16.92 ± 0.68%). Also the per-
centageapoptoticnucleicountincreased indaidzein(17.94±
0.46%, P<0.001) and EB (18.82 ± 0.71%, P<0.001), com-
pared to the control (13.28±0.42%),at 50 days, signiﬁcantly
(Figures 2–5).
4.Discussion
Our data clearly demonstrates, the prepubertal exposure to
daidzein by the female Sprague Dawley rats produces an en-
hancement in the diﬀerentiation of the mammary gland as
well asinﬂuencesapoptosisandtheERexpression. The high-
est susceptibility of a rat mammary gland to a carcinogen
occurs in the postpubertal virgin females around the age of
50 days, which correlates well with the higher number of
TEBs and the high cell proliferation, and a low incidence of
mammary carcinoma is related to the loss of TEBs and the
low cell proliferation activity [24].
There was an increase in the count of TEBs and TDs
and lobules by the prepubertal administration of daidzein in
PND21, which shows an increased proliferation in the cells,
which is probably necessary for the developing of mammary
gland at a prepubertal stage. Lobules are more stable
structures than the TEBs and TDs, hence, by the increase in
the countoflobules,itcouldbeinterpreted that theundiﬀer-
entiated TEBs and TDs are progressing gradually towards the
formation ofmore diﬀerentiatedlobules,which couldbe due
to the inﬂuence of daidzein. In a similar kind of study with
genistein,itwasobservedthatprepubertalgenisteinexposure
increases the count of TEBs and lobules at PND21 [19, 23].
A tP N D 5 0 ,t h ed e c r e a s ei nt h ec o u n to fT E B sa n dT D si n d i -
cated a decreased proliferation, and coupling this with an in-
crease in count of lobules at the same time suggests further
enhancement in the diﬀerentiation of mammary glands at
pubertal stage, in daidzein-treated mammary glands. Ear-
lier genistein had shown a similar potential to increase the
mammary glanddiﬀerentiation,alongwithreductionofTEB
count and increase in the lobules, at PND50 [19, 23]. Some6 ISRN Oncology
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Figure 4:Eﬀect ofdaidzein (500μg/g bwt) onBax.(a)ImmunohistochemistryofER-α in prepubertal femaleSprague Dawley ratsat PND21
andPND50. (b) meanpercent change ± SEMofER-α+ cell countand(c)mean ±SEM ofdensitometric analysis,from6animals. ∗P<0.05,
∗∗P<0.01, ∗∗∗P<0.001, compared to the respective value in control group.
of the xenoestrogens such as diethylstilbestrol (DES), o,p -
DDT, Aroclor 1221, Aroclor 1254, and 2,3,7,8-tetrachlorodi-
benzo-p-dioxin (TCDD)also showed an enhancement in the
mammary gland diﬀerentiation when administered prepu-
bertally [25]. Since the development of mammary gland is
controlled by female reproductive hormones like estrogen, it
is likely that exogenously the administration of the estrogen
agonist estradiol benzoate (EB) will show an enhancement
in the mammary gland development, which has also been
reported earlier [26]. Here, the EB-treated mammary glands
also showed an increase in the TEBs and TDs at PND21
and a decrease in the TEBs and TDs count along with the
increase in lobules at the old mammary gland PND50. A
similarity in the results of both EB-and daidzein-treated
mammary gland diﬀerentiation data suggests that daidzein
mighthaveasimilarmodeandmagnitudeofactionasthatof
EB, when administered to rats during the prepubertal stage.
Thus, theoverallresultsofthemammary diﬀerentiationdata
reveals that shortly after exposure to daidzein, there was a
rapid development of the mammary gland, yielding more
diﬀerentiated structures (lobules)and fewer undiﬀerentiated
structures (terminal end buds).
Tumorigenesis experiments done earlier in our labora-
tory had also shown a decrease in tumour incidence and
burdenbytreatmentofdaidzeintoSDratsintheprepubertal
stage [21]. Hencethis chemopreventiveeﬀectofdaidzein can
be correlated to the increased diﬀerentiation rate of mam-
mary gland caused by the prepubertal exposure of com-
pound.
ER-α plays a large role in mammary gland development.
Immunohistochemical data of ER-α indicated that there is
a decreased expression of ER-α in response to Daidzein,
seen in the mammary epithelial cells at PND21. Normally,
the percentage of ER-α-positive nuclei varies according to
the developmental state of the mammary gland. Decreased
expression of ER-α may also reﬂect proliferation, as prolifer-
ating epithelial cells of the mammary glands of young virgin
rats do not express the receptor [27, 28], while its increase
a f t e r5 0d a y ss u g g e s t st h a tE R - α expression might not be
somewhat necessary for proliferation but may be requiredISRN Oncology 7
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Figure 5: Eﬀect of daidzein (500μg/g bwt) on caspase-3 count. (a) Immunohistochemistry of ER-α in prepubertal female Sprague Dawley
rats at PND21 and PND50. (b) mean percent change ± SEM of Caspase-3+ cell count. Each bar represents the average ± SEM from 6
animals. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, compared to the respective value in control group.
for the diﬀerentiation of mammary glands. This is consistent
with our previous results which indicated that prepuber-
tal daidzein treatment resulted in a proliferative mammary
gland at PND21, which led to a more diﬀerentiated structure
evident at PND50. A similar result in the expression of ER-
α in response to daidzein and EB may suggest a common
molecular mechanism of action.
There has been a link established between the proliferat-
ing epithelial cells and the expression of ER-α in developing
rodent mammary gland. The increase in the count and
intensity of Bcl2 at PND21 further supported the result that
there might be an increase in proliferation of cells which
might have resulted in the increased count of the unstable
proliferating structure, TEBs, accordingly. Later at PND50,
there is a decrease in the Bcl2 expression which indicates
decreased proliferation. This can be related to the enhanced
diﬀerentiation of the mammary glands in the daidzein-
treated rats, where there was an increase in the lobule count
along with a decrease in the count of TEB at PND50.
And since the diﬀerentiation of the cells has increased and
proliferation has slowed down, the count of Bcl2 has also
decreased in 50-day-old daidzein-treated rats, signiﬁcantly,
as compared to control. Furthermore, a decrease in the level
of antiapoptotic protein Bax at PND21 and its increase in
PND50 show that apoptosis is not seen in PND21 rather
it increased in PND50 as evaluated by the simultaneous
expression levels of Bcl2 and Bax. The process of apoptosis
is integral tonormal mammary gland development[28],and
themorphogenesisofductsin thedevelopmentofmammary
gland is dependent on the selective death of epithelial cells to
form mammary acini [29, 30].
Nuclear condensation and fragmentation because of
degradation of DNA into oligonucleosome fragments [31],
which is a characterized feature of apoptosis, was seen to be
increased in PND50, whereas no signiﬁcant change in the
apoptotic level was observed at PND21. This was further
conﬁrmed when the apoptotic marker protein, caspase-3,
which is also known to be one of the principal intracellular
eﬀectors of the apoptotic cascade, simultaneously increased
in the daidzein-and EB-treated cells along with the increase
in apoptotic nuclei, at PND50.
Since daidzein and EB decrease the expression of ER-α
in prepubertal epithelial cells along with the increase in the
proliferation and diﬀerentiation of cells at the same time,
it can be said that the estrogen receptor expression and the
mechanism for the proliferation of cells may not be directly
correlated, and both proteins might have been inﬂuenced by
thetest compoundbyseparate pathways.Bothprocesses may
be independentofeach other, butbothmight be requiredfor
the enhancement of diﬀerentiation of the gland.
5.Conclusion
The phytoestrogen daidzein has a potential to regulate the
diﬀerentiation of mammary gland by maintaining a balance8 ISRN Oncology
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Figure 6:Eﬀect of daidzein (500μg/g bwt) onlevel ofapoptosisthrough Hoechst (33258)staining.(a) Pictomicrographsshowingapoptotic
nuclei in prepubertal female Sprague Dawley rats at PND21 and PND50. (b) mean percent change ± SEM of apoptotic nuclei count, in
PND21 as well as PND50 mammary glands. Each bar represents the average ± SEM from 6 animals. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001,
compared to the respective value in control group.
between proliferation and apoptotic death of the cells which
is critical for its normal development. Perturbations in
this balance can contribute to the development of various
disorders in mammary gland including cancer. Conditions
that upregulate cell proliferation or downregulate apoptosis
can allow the accumulation of mutations that contribute
to the subsequent development of breast cancer. Daidzein
enhances the diﬀerentiation of mammary gland in a con-
trolled manner at all the developmental stages. Although
the inﬂuence of daidzein on some key proliferative and
apoptotic proteins has been discussed here, investigations
on other cellular pathways integral to the diﬀerentiation
processcan beexplored tohave a betterunderstanding of the
mechanism of actions of daidzein. Thus, it can be concluded
that daidzein, in a similar mechanism of action as that of
EB, inﬂuences the diﬀerentiation of mammary gland by
aﬀecting cell proliferation proteins and the ER-α expression.
Since the more diﬀerentiated the mammary gland is, the less
susceptibleitistocancerincidence,dietaryintakeofdaidzein
from an early developmental stages may be beneﬁcial to
women folk in particular, which can be further conﬁrmed
through clinical trials.
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